Global Molecular Diagnostic Market is expected to reach US$ 18.6 billion by 2028, registering a CAGR of over 12.1% during 2023-2028
09. August 2023 08:04 ET
|
Rationalstat LLC
Wilmington,Delaware, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Market Scope and Report Overview Market intelligence for the global molecular diagnostic market covers market sizes on the basis of...
Interpace Biosciences Announces Divestiture of New Haven CLIA lab to DiamiR
17. März 2021 07:30 ET
|
Interpace Biosciences, Inc.
Part of Company’s Site Consolidation and Cost Savings Measures Parsippany, NJ, March 17, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTC: IDXG) announced today that it has entered into...
Fluidigm Announces Conference Call and Webcast of Third Quarter 2020 Financial Results
06. Oktober 2020 16:02 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Fluidigm to Participate at the 2020 Cantor Virtual Global Healthcare Conference
02. September 2020 16:02 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Interpace Diagnostics Ranked as Top 10 Bioinformatics Solutions Provider
27. Dezember 2018 06:55 ET
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Dec. 27, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that CIO Applications, a publication focused on providing professionals with...
Admera Health Genetic Tests are Now In-Network with CareFirst BlueCross BlueShield, Maryland, Washington D.C, and Northern Virginia
11. Dezember 2018 09:13 ET
|
Admera Health, LLC
SOUTH PLAINFIELD, N.J., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Admera Health (www.admerahealth.com), an advanced molecular diagnostics company, announced today that its genetic testing services are now...
Newly Published Data from National Study Supports Interpace Diagnostics’ PancraGEN®
26. November 2018 06:55 ET
|
Interpace Diagnostics Group, Inc.
New Article in Peer-Reviewed Journal Highlights Important Role of PancraGEN® Testing PARSIPPANY, NJ, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG)...
Interpace Diagnostics Announces New Coverage by Blue Cross Blue Shield for Thyroid Testing
07. November 2018 08:06 ET
|
Interpace Diagnostics Group, Inc.
The Federal Employee Health Benefit BCBS Program Adds Approximately 5.3 Million Covered Lives PARSIPPANY, NJ, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG)...
Fluidigm and Ascendas Genomics Announce Strategic Partnership to Develop Microfluidic Molecular Diagnostics in China
27. Juli 2017 16:05 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif. and ZHONGSHAN, China, July 27, 2017 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) and Ascendas Genomics today announced a strategic partnership to develop...